Literature DB >> 30123863

Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.

Zofia Piotrowska1, Mehlika Hazar-Rethinam1, Coleen Rizzo1, Brandon Nadres1, Emily E Van Seventer1, Heather A Shahzade1, Inga T Lennes1, Anthony J Iafrate1, Dora Dias-Santagata1, Ignaty Leshchiner2, Nicholas A Jessop1, Haichuan Hu1, Subba R Digumarthy1, Rebecca J Nagy3, Richard B Lanman3, Susan Moody4, Matthew J Niederst4, Jeffrey A Engelman4, Aaron N Hata1, Ryan B Corcoran1, Lecia V Sequist1.   

Abstract

PURPOSE: Third-generation epidermal growth factor receptor (EGFR) inhibitors like nazartinib are active against EGFR mutation-positive lung cancers with T790M-mediated acquired resistance to initial anti-EGFR treatment, but some patients have mixed responses.
METHODS: Multiple serial tumor and liquid biopsies were obtained from two patients before, during, and after treatment with nazartinib. Next-generation sequencing and droplet digital polymerase chain reaction were performed to assess heterogeneity and clonal dynamics.
RESULTS: We observed the simultaneous emergence of T790M-dependent and -independent clones in both patients. Serial plasma droplet digital polymerase chain reaction illustrated shifts in relative clonal abundance in response to various systemic therapies, confirming a molecular basis for the clinical mixed radiographic responses observed.
CONCLUSION: Heterogeneous responses to treatment targeting a solitary resistance mechanism can be explained by coexistent tumor subclones harboring distinct genetic signatures. Serial liquid biopsies offer an opportunity to monitor clonal dynamics and the emergence of resistance and may represent a useful tool to guide therapeutic strategies.

Entities:  

Year:  2018        PMID: 30123863      PMCID: PMC6097183          DOI: 10.1200/PO.17.00263

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN: 2473-4284


  24 in total

1.  Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.

Authors:  Gee-Chen Chang; Chien-Hua Tseng; Kuo-Hsuan Hsu; Chong-Jen Yu; Cheng-Ta Yang; Kun-Chieh Chen; Tsung-Ying Yang; Jeng-Sen Tseng; Chien-Ying Liu; Wei-Yu Liao; Te-Chun Hsia; Chih-Yen Tu; Meng-Chih Lin; Ying-Huang Tsai; Meng-Jer Hsieh; Wen-Shuo Wu; Yuh-Min Chen
Journal:  Lung Cancer       Date:  2016-12-14       Impact factor: 5.705

2.  Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Authors:  Giulia Siravegna; Benedetta Mussolin; Michela Buscarino; Giorgio Corti; Andrea Cassingena; Giovanni Crisafulli; Agostino Ponzetti; Chiara Cremolini; Alessio Amatu; Calogero Lauricella; Simona Lamba; Sebastijan Hobor; Antonio Avallone; Emanuele Valtorta; Giuseppe Rospo; Enzo Medico; Valentina Motta; Carlotta Antoniotti; Fabiana Tatangelo; Beatriz Bellosillo; Silvio Veronese; Alfredo Budillon; Clara Montagut; Patrizia Racca; Silvia Marsoni; Alfredo Falcone; Ryan B Corcoran; Federica Di Nicolantonio; Fotios Loupakis; Salvatore Siena; Andrea Sartore-Bianchi; Alberto Bardelli
Journal:  Nat Med       Date:  2015-07       Impact factor: 53.440

3.  Comparative Performance of Reagents and Platforms for Quantitation of Cytomegalovirus DNA by Digital PCR.

Authors:  R T Hayden; Z Gu; S S Sam; Y Sun; L Tang; S Pounds; A M Caliendo
Journal:  J Clin Microbiol       Date:  2016-08-17       Impact factor: 5.948

4.  Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.

Authors:  Helena A Yu; Shaozhou K Tian; Alexander E Drilon; Laetitia Borsu; Gregory J Riely; Maria E Arcila; Marc Ladanyi
Journal:  JAMA Oncol       Date:  2015-10       Impact factor: 31.777

5.  Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.

Authors:  Andrew J Weickhardt; Benjamin Scheier; Joseph Malachy Burke; Gregory Gan; Xian Lu; Paul A Bunn; Dara L Aisner; Laurie E Gaspar; Brian D Kavanagh; Robert C Doebele; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2012-12       Impact factor: 15.609

6.  Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Authors:  Helena A Yu; Maria E Arcila; Natasha Rekhtman; Camelia S Sima; Maureen F Zakowski; William Pao; Mark G Kris; Vincent A Miller; Marc Ladanyi; Gregory J Riely
Journal:  Clin Cancer Res       Date:  2013-03-07       Impact factor: 12.531

7.  Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib.

Authors:  Chao-Chi Ho; Wei-Yu Liao; Chih-An Lin; Jin-Yuan Shih; Chong-Jen Yu; James Chih-Hsin Yang
Journal:  J Thorac Oncol       Date:  2016-12-05       Impact factor: 15.609

8.  Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.

Authors:  Ken Uchibori; Naohiko Inase; Mitsugu Araki; Mayumi Kamada; Shigeo Sato; Yasushi Okuno; Naoya Fujita; Ryohei Katayama
Journal:  Nat Commun       Date:  2017-03-13       Impact factor: 14.919

9.  Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.

Authors:  Yong Jia; Cai-Hong Yun; Eunyoung Park; Dalia Ercan; Mari Manuia; Jose Juarez; Chunxiao Xu; Kevin Rhee; Ting Chen; Haikuo Zhang; Sangeetha Palakurthi; Jaebong Jang; Gerald Lelais; Michael DiDonato; Badry Bursulaya; Pierre-Yves Michellys; Robert Epple; Thomas H Marsilje; Matthew McNeill; Wenshuo Lu; Jennifer Harris; Steven Bender; Kwok-Kin Wong; Pasi A Jänne; Michael J Eck
Journal:  Nature       Date:  2016-05-25       Impact factor: 49.962

10.  Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

Authors:  Jacob J Chabon; Andrew D Simmons; Alexander F Lovejoy; Mohammad S Esfahani; Aaron M Newman; Henry J Haringsma; David M Kurtz; Henning Stehr; Florian Scherer; Chris A Karlovich; Thomas C Harding; Kathleen A Durkin; Gregory A Otterson; W Thomas Purcell; D Ross Camidge; Jonathan W Goldman; Lecia V Sequist; Zofia Piotrowska; Heather A Wakelee; Joel W Neal; Ash A Alizadeh; Maximilian Diehn
Journal:  Nat Commun       Date:  2016-06-10       Impact factor: 14.919

View more
  6 in total

1.  Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies.

Authors:  Aaron N Hata; Harald Paganetti; Clemens Grassberger; David McClatchy; Changran Geng; Sophia C Kamran; Florian Fintelmann; Yosef E Maruvka; Zofia Piotrowska; Henning Willers; Lecia V Sequist
Journal:  Cancer Res       Date:  2019-05-21       Impact factor: 12.701

2.  Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor-Mutant Lung Cancer.

Authors:  Florian J Fintelmann; Fabian M Troschel; Martin W Kuklinski; Shaunagh McDermott; Milena Petranovic; Subba R Digumarthy; Amita Sharma; Amelie S Troschel; Melissa C Price; Lida P Hariri; Matthew D Gilman; Joanne O Shepard; Lecia V Sequist; Zofia Piotrowska
Journal:  Oncologist       Date:  2019-05-31

3.  Nondestructive protein sampling with electroporation facilitates profiling of spatial differential protein expression in breast tumors in vivo.

Authors:  Edward Vitkin; Amrita Singh; Zohar Yakhini; Alexander Golberg; Julia Wise; Shay Ben-Elazar
Journal:  Sci Rep       Date:  2022-09-23       Impact factor: 4.996

4.  Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer.

Authors:  Bernard Pereira; Christopher T Chen; Lipika Goyal; Charlotte Walmsley; Christopher J Pinto; Islam Baiev; Read Allen; Laura Henderson; Supriya Saha; Stephanie Reyes; Martin S Taylor; Donna M Fitzgerald; Maida Williams Broudo; Avinash Sahu; Xin Gao; Wendy Winckler; A Rose Brannon; Jeffrey A Engelman; Rebecca Leary; James R Stone; Catarina D Campbell; Dejan Juric
Journal:  Nat Commun       Date:  2021-05-27       Impact factor: 14.919

Review 5.  Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer.

Authors:  Ana I Velazquez; Caroline E McCoach
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005

6.  The Discordance of Gene Mutations between Circulating Tumor Cells and Primary/Metastatic Tumor.

Authors:  Qi Wang; Lanbo Zhao; Lu Han; Xiaoqian Tuo; Sijia Ma; Yiran Wang; Xue Feng; Dongxin Liang; Chao Sun; Qing Wang; Qing Song; Qiling Li
Journal:  Mol Ther Oncolytics       Date:  2019-08-29       Impact factor: 7.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.